I’ve nearing the end of my series on vaccination (at least one more topic to come), but I’ll change it up here with some short information about treatment, specifically the treatment of Lyme disease.
One challenge we have with infectious diseases of animals is determining optimal durations of treatment. We tend to have very little data, but often well ingrained positions, dogma or habits. Most likely, we overtreat. Durations that are used for treatment of many infectious diseases are longer than are used in comparable diseases in humans and are hard to justify based on any other principles or data. We’re making progress in some areas (e.g. decreasing duration of treatment of bacterial cystitis, guided by our ISCAID guidelines) but we still have a long way to go.
A lot of duration recommendations are from expert opinion. That’s not inherently bad (since you have to start somewhere and in the absence of data, a good, unbiased expert can help). But, we should aim higher. Ideally, we’d start with expert opinion when needed, then backfill it with data to find out what the optimal duration is and make necessary changes.
That doesn’t happen very often. There are lots of reasons for that, including lack of funding for proper trials, a pretty small pool of us interested in infectious diseases and reluctance to change. We’re often comfortable with what we are doing and don’t want to change, even when we we’re doing isn’t evidence based.
Lyme disease is a great example of a disease where we have very little actual data (and lots of opinion).
Led by Dr. Fiona Emdin, we have a commentary out in the Journal of the American Veterinary Medical Association that discusses our common approaches for treatment of Lyme disease and the need for proper assessment. (Approaches to Lyme nephritis have even bigger issues, but I’ll maybe cover that later).
The commentary is fire-walled, unfortunately, but here’s the abstract for those that don’t have access.
Canine Lyme borreliosis is commonly treated with a 28-day course of doxycycline, a regimen based on historical precedent rather than evidence. Most dogs exposed to Borrelia burgdorferi remain clinically normal despite seroconversion; of those that do develop clinical Lyme disease, the most common presentation is acute or recurrent shifting-leg lameness consistent with Lyme arthropathy. This Viewpoint proposes there is clinical equipoise to evaluate shorter durations of 10 days of doxycycline in dogs with uncomplicated Lyme arthropathy and outlines a prospective parallel-group randomized controlled trial to reassess treatment duration. Determining whether a shorter treatment course is clinically effective also has important implications for antimicrobial stewardship by minimizing unnecessary antimicrobial exposure and selection pressures for antimicrobial resistance.








